MedTrace Logo

Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis

NCT03518502 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2018-05-08

No results posted yet for this study

Summary

Sorafenib is the standard therapy for hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM). However, addition of transarterial chemoembolization (TACE) may be beneficial for controlling intrahepatic tumour. The investigators aimed to compare the efficacy between the sorafenib monotherapy and TACE-sorafenib sequential therapy in HCC patients with EHM.

Conditions

Interventions

PROCEDURE

transarterial chemoembolization (TACE)

Standard therapy for intermediate HCC, but nor for advanced HCC

DRUG

Sorafenib

Standard therapy for advanced HCC

Sponsors & Collaborators

  • Korean Liver Cancer Study Group

    collaborator OTHER

  • Korea University

    lead OTHER

Principal Investigators

  • Hyung Joon Yim, M.D. · Korea University Ansan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-01
Primary Completion
2020-02-28
Completion
2022-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03518502 on ClinicalTrials.gov